SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: S-1/A
Date Filed: 2026-05-15
Accession Number: 0001493152-26-023752
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226023752/forms-1a.htm

Chunk 63 of 94
Word Count: 1493
Character Count: 9466

Document Content:

Name and Address of Beneficial Owner (1) Number (7) (8) Percentage (2) Number Percentage (3) Executive Officers and Directors Steve Chartier 189,155 1.36 % * Ori Ben-Yehuda 110,000 * % David Richmond 4,312,921 (4) 31.00 % % Carl E. Byrnes, Jr. - - % Mark Ravich 1,108,197 (6) 7.97 % % Rishi Puri 6,250 * % William T. Abraham 6,250 * % All directors and executive officers as a group (7 individuals) 5,732,773 41.21 % % 5% or Greater Stockholders Michael Taglich 1,128,499 (5) 8.11 % [●] % Less than 1%. (1) Except as otherwise indicated, the business address of our directors and executive officers is 120 Forbes Blvd., Suite 125, Mansfield, MA (2) Based on 13,912,438 shares of common stock outstanding as of the date of this prospectus. (3) Based on [●] shares of common stock outstanding immediately after this offering assuming no exercise of the underwriters’ over-allotment option.

(4)	Includes
(a) 261,646 shares of common stock comprised of 194,000 shares of common stock directly held by Mr. Richmond (including 44,000
shares of common stock from restricted stock grants) and 67,646 common stock subject to options that are currently exercisable
or exercisable within 60 days of the date of this prospectus, (b) 2,619,685 shares of common stock, comprised of 148,400
Series A shares convertible into 148,400 common stock and $2,471,285 Series A Secured Convertible Notes convertible
into 2,471,285 shares of common stock held by RBI BioVentrix LLC, (c) 478,314 shares of common stock comprised of 385,832
shares of common stock, 75,391 Series A shares convertible into 75,391 shares of common stock, and $85,454 Series A-2 Secured
Convertible Notes convertible into 17,091 shares of common stock held by RBI Opportunities Fund LLC, (d) 355,595 shares of common
stock comprised of 311,668 shares of common stock and 43,927 Series A shares convertible into 43,927 shares of common stock
held by RBI BV Private Investment, (e) 294,681 common shares comprised of 226,025 shares of common stock, 51,565 Series
A shares convertible into 51,565 shares of common stock, and $85,454 Series A-2 Secured Convertible Notes convertible into 17,091
shares of common stock held by RBI Private Investment III LLC, (f) 272,831 shares, comprised of 215,077 shares of common
stock, 40,663 Series A shares convertible into 40,633 shares of common stock, and $85,454 Series A-2 Secured Convertible
Notes convertible into 17,091 shares of common stock held by RBI Opportunities Fund II LLC, (g) 11,199 shares comprised of 8,300
shares of common stock and 2,899 Series A shares convertible into 2,899 shares of common stock held by David Richmond &
Stephanie Richmond, (h) 9,486 shares comprised of 8,123 shares of common stock and 1,363 Series A shares convertible into 1,363
shares of common stock held by RBI Private Investment I LLC, and (i) 9,485 shares, comprised of 8,123 shares of common stock
and 1,362 Series A shares convertible into 1,362 shares of common stock held by Richmond Brothers Inc. Mr. Richmond is the
Manager and has voting and investment control of RBI BioVentrix LLC, RBI Opportunities Fund LLC, RBI BioVentrix, LLC, RBI BV Private
Investment, RBI Private Investment III LLC, RBI Opportunities Fund II LLC, David Richmond & Stephanie Richmond, RBI Private Investment
I LLC, and Richmond Brothers Inc, (collectively, the “Richmond Entities”). Mr. Richmond disclaims any beneficial ownership
of the securities held by the Richmond Entities, other than to the extent of any pecuniary interest he may have therein, directly
or indirectly.

(5)	Includes
(a) 119,903 shares of common stock directly held by Mr. Taglich, (b) 103,654 shares of common stock held by Taglich Brothers
Inc., (c) 84,408 shares of common stock held by Michael N. Taglich & Claudia Taglich, (d) 177 shares of common stock held by
Claudia Ruggiero Taglich, (e) 3,179 shares of common stock held by Michael Taglich C/F Amanda Taglich UTMA NY, (f) 3,179 shares of
common stock held by Michael Taglich C/F Lucy Taglich UTMA NY, (g) 3,179 shares of common stock held by Michael Taglich C/F Stella
Taglich UTMA NY, (h) 130,142 shares of common stock held by Michael N. Taglich Keogh Account, (i) 3,179 shares of common stock held
by Michael Taglich TTEE Hope A Taglich Supplemental Needs Trust UAD 8/23/17, and (j) 677,500 Series A shares convertible into 677,500
shares of common stock held by Bioventrix investors LLC. Mr. Taglich is the President of Taglich Brothers Inc., Michael N. Taglich
Keogh Account, Michael Taglich TTEE Hope A Taglich Supplemental Needs Trust UAD 8/23/17, and Bioventrix investors LLC and has voting
and investment control over the shares held by Michael N. Taglich & Claudia Taglich, Claudia Ruggiero Taglich, Michael Taglich
C/F Amanda Taglich UTMA NY, Michael Taglich C/F Lucy Taglich UTMA NY, and Michael Taglich C/F Stella Taglich UTMA NY (collectively,
the “Taglich Entities”). Mr. Taglich disclaims any beneficial ownership of the securities held by the Taglich Entities,
other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

(6)	Includes
(a) 171,250 shares of common stock comprised of 165,000 common shares directly held by Mr. Ravich (including 99,000
common shares from restricted stock grants) and 6,250 common stock subject to options that are currently exercisable or exercisable
within 60 days of the date of this prospectus, (b) 30,074 common shares comprised of 10,000 Series A shares convertible into
10,000 shares of common stock and $100,370 Series A-2 Secured Convertible Notes convertible into 20,074 shares of common stock
held by Mark Ravich Irrevocable Trust, (c) 259,000 common shares comprised of 79,880 Series A shares convertible into 79,880
shares of common stock, $137,210 Series A Secured Convertible Notes convertible into 137,210 shares of common stock, $106,139
Series A-1 Secured Convertible Notes convertible into 31,874 shares of common stock, and $50,185 Series A-2 Secured Convertible
Notes convertible into 10,037 shares of common stock held by Mark Ravich Revocable Trust, (d) 380,650 common shares comprised
of 93,590 common shares, 10,000 Series A shares convertible into 10,000 shares of common stock, and $277,060 Secured
Convertible Notes convertible into 277,060 shares of common stock held by Mark Ravich TTEE Mark Ravich Irrevocable Trust UAD
11/05/18, (e) 87,938 common shares held by Mark H. Ravich TTEE Revocable Trust of Mark H. Ravich UAD 10/08/19, (f) 83,363
common shares comprised of 5,000 Series A shares convertible into 5,000 shares of common stock, $68,326 Secured Convertible
Notes convertible into 68,326 shares of common stock, and $50,185 Series A-2 Secured Convertible Notes convertible into 10,037
shares of common stock held by Norman and Sally Ravich Family Trust, (g) 40,261 common shares held by Mark Ravich TTEE Cindy
Libman Irrevocable Trust UAD 11/05/18, (h) 17,482 common shares held by Mark H. Ravich TTEE Norman & Sally Ravich Family Trust
UAD 12/24/92, (i) 8,123 common shares held by Alexander Coleman Ravich 1991 Irrevocable Trust, (j) 8,123 common shares held by Alyssa
Danielle Ravich 1991 Irrevocable Trust, and (k) 21,933 common shares comprised $54,807 Secured Convertible Notes convertible
into 16,548 shares of common stock held by Ilyne Ravich. Mr. Ravich is the Trustee and has voting and investment control of Mark
Ravich Irrevocable Trust, Revocable Trust of Mark Ravich, Mark Ravich TTEE Mark Ravich Irrevocable Trust UAD 11/05/18, Mark H. Ravich
TTEE Revocable Trust of Mark H. Ravich UAD 10/08/19, Norman and Sally Ravich Family Trust, Mark Ravich TTEE Cindy Libman Irrevocable
Trust UAD 11/05/18, Mark H. Ravich TTEE Norman & Sally Ravich Family Trust UAD 12/24/92, Alexander Coleman Ravich 1991 Irrevocable
Trust, and Alyssa Danielle Ravich 1991 Irrevocable Trust (collectively, the “Ravich Entities”). Mr. Ravich disclaims
any beneficial ownership of the securities held by the Ravich Entities, other than to the extent of any pecuniary interest he may
have therein, directly or indirectly.

(7)	For
note conversions into shares assumes that interest accrues through April 30, 2026.

(8)	The
Secured Convertible Notes convert into our common stock subject to an initial public offering
generating $7.5 million of gross proceeds. We have assumed the initial public offering price
is at least $10.00 per share, generating gross proceeds of $[   ]. Each
$1.00 decrease in the assumed initial public offering price of $
per share (the midpoint of the estimated price range set forth on the cover page of this
prospectus) below $10.00 per share would increase the number of shares issued upon
the conversion by approximately $        , assuming the
number of shares, as set forth on the cover page of this prospectus, remains the same and
after deducting underwriting discounts and estimated offering expenses payable by us.

CERTAIN
RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

During
the period from January 1, 2023 to the date of this prospectus, we have entered into or participated in the following transactions with
related persons:

April 17, 2026, entities controlled by David Richmond purchased $255,000 of Series A-2 Secured Convertible Notes.

April 21, 2026, entities controlled by Mark Ravich purchased $200,000 of Series A-2 Secured Convertible Notes.

January 8, 2026, a related party Michael Taglich returned 262,050 shares of the Company’s Series A preferred stock to the Company
in a nonreciprocal transfer.